The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis

被引：3

作者：

Cha, Danielle S. ^{[1
,2
,3
,4
,5
]}

Kleine, Nicholas ^{[4
,6
]}

Teopiz, Kayla M. ^{[4
,6
]}

Di Vincenzo, Joshua D. ^{[3
,4
]}

Ho, Roger ^{[7
,8
]}

Galibert, Stephanie L. ^{[9
]}

Samra, Amrita ^{[5
]}

Zilm, Samuel P. M. ^{[5
]}

Cha, Rebekah H. ^{[10
]}

d'Andrea, Giacomo ^{[8
]}

Gill, Hartej ^{[3
,11
]}

Ceban, Felicia ^{[3
,4
,10
]}

Meshkat, Shakila ^{[3
]}

Wong, Sabrina ^{[3
,4
]}

Le, Gia Han ^{[3
,11
]}

Kwan, Angela T. H. ^{[3
,11
]}

Rosenblat, Joshua D. ^{[3
,4
,12
]}

Rhee, Taeho Greg ^{[13
,14
]}

Mansur, Rodrigo B. ^{[3
,4
]}

Mcintyre, Roger S. ^{[15
,16
,17
,18
,19
,20
,21
,22
,23
]}

机构：

[1] Royal Brisbane & Womens Hosp, Mental Hlth Serv, Brisbane, Qld, Australia

[2] Univ Queensland, Sch Clin Med, Royal Brisbane Clin Unit, Brisbane, Qld, Australia

[3] Brain & Cognit Fdn, Toronto, ON, Canada

[4] Univ Hlth Network, Toronto Western Hosp, Mood Disorders Psychopharmacol Dept, Toronto, ON, Canada

[5] Royal Brisbane & Womens Hosp, Metro North Hosp & Hlth Serv, Brisbane, Qld, Australia

[6] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada

[7] Natl Univ Singapore, Inst Hlth Innovat & Technol iHealthtech, Singapore, Singapore

[8] Univ G dAnnunzio, Dept Neurosci Imaging & Clin Sci, Chieti, Italy

[9] Logan Hosp, Dept Obstet & Gynaecol, Logan, Qld, Australia

[10] McMaster Univ, Michael G DeGroote Sch Med, Hamilton, ON, Canada

[11] Univ Toronto, Inst Med Sci, Toronto, ON, Canada

[12] Univ Toronto, Dept Psychiat, Toronto, ON, Canada

[13] Yale Sch Med, Dept Psychiat, New Haven, CT USA

[14] Univ Connecticut, Sch Med, Dept Publ Hlth Sci, Farmington, CT USA

[15] Univ Toronto, Dept Psychiat & Pharmacol, Toronto, ON, Canada

[16] Brain & Cognit Discovery Fdn BCDF, Toronto, ON, Canada

[17] Depress & Bipolar Support Alliance DBSA Board Dire, Board Chair, Chicago, IL USA

[18] Guangzhou Med Univ, Guangzhou, Peoples R China

[19] Korea Univ, Coll Med, Seoul, South Korea

[20] Univ Philippines, Coll Med, Manila, Philippines

[21] SUNY Upstate Med Univ, State Univ New York, Syracuse, NY USA

[22] Univ Calif Riverside, Sch Med, Dept Psychiat & Neurosci, Riverside, CA USA

[23] Univ Toronto, 77 Bloor St West,6th Floor Suite 617, Toronto, ON M5S 1M2, Canada

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2024年 / 25卷 / 01期

基金：

中国国家自然科学基金; 加拿大健康研究院;

关键词：

Zuranolone; SAGE217; depression; postpartum/postpartum depression; rapid-acting; neuroactive steroid; GABA(A); positive allosteric modulator; COGNITIVE FUNCTION; ALLOSTERIC MODULATORS; MENTAL-DISORDERS; CLINICAL-TRIAL; IMPACT; HARM; ALPHAXALONE; OUTPATIENTS; IMPAIRMENT; LIKELIHOOD;

D O I：

10.1080/14656566.2023.2298340

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Major depressive disorder (MDD) is a common and debilitating mental illness. Postpartum depression (PPD) impacts women globally and is one of the most common complications of childbirth that is underdiagnosed and undertreated, adversely impacting the mental health of women, children, and partners. Available antidepressant medications require weeks to months before showing effect. In this setting, zuranolone, an oral neuroactive steroid and a positive allosteric modulator of GABA(A) receptors, is an attractive alternative as a rapid-acting antidepressant treatment.Areas covered: This article reviews zuranolone (SAGE217), focusing on available clinical studies in individuals with PPD and MDD. This paper adds to the extant literature by presenting the efficacy data as Number Needed to Treat (NNT) to facilitate indirect comparisons with other antidepressants.Expert opinion: Zuranolone is a novel rapid-acting (i.e. two week course) oral antidepressant for the treatment of adults with PPD with ongoing clinical trials evaluating its efficacy in adults with MDD. Zuranolone is well tolerated with no significant safety concerns in any clinical trials completed to date. Zuranolone will be scheduled by the Drug Enforcement Agency (DEA).

引用

页码：5 / 14

页数：10

共 50 条

[21] Different dosage regimens of zuranolone in the treatment of major depressive disorder: A meta-analysis of randomized controlled trials
Lian, Jinrong
Lin, Zhimin
Li, Xiang
Chen, Gang
Wu, Depei
JOURNAL OF AFFECTIVE DISORDERS, 2024, 354 : 206 - 215
[22] The efficacy of vortioxetine in the acute treatment of major depressive disorder: A systematic review and meta-analysis
Berardelli, Isabella
Rogante, Elena
Formica, Federico
Iannazzo, Riccardo
Mammoliti, Attilio Valerio
Riccioni, Raffaele
Veizi, Skender
Mcintyre, Roger S.
Pompili, Maurizio
JOURNAL OF PSYCHOPHARMACOLOGY, 2025, 39 (02) : 92 - 105
[23] Efficacy and tolerability of antidepressants for sub-threshold depression and for mild major depressive disorder
Cameron, Isobel M.
Reid, Ian C.
MacGillivray, Steve A.
JOURNAL OF AFFECTIVE DISORDERS, 2014, 166 : 48 - 58
[24] Improvement in Depressive Symptoms With Zuranolone Treatment in Patients With Major Depressive Disorder With or Without Elevated Anxiety: Pooled Analysis From the MDD-201B, MOUNTAIN, and WATERFALL Studies
Czysz, Andrew
Nemeroff, Charles
Schatzberg, Alan
Lasser, Robert
Park, Lawrence
Toubouti, Youssef
Forrestal, Fiona
Iovin, Ramon
Jonas, Jeffery
NEUROPSYCHOPHARMACOLOGY, 2022, 47 (SUPPL 1) : 201 - 202
[25] An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder
Carrasco, Jose L.
Kornstein, Susan G.
McIntyre, Roger S.
Fayyad, Rana
Prieto, Rita
Salas, Maribel
Mackell, Joan
Boucher, Matthieu
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2016, 31 (03) : 134 - 146
[26] The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: A systematic review and meta-analysis
Meeker A.S.
Herink M.C.
Haxby D.G.
Hartung D.M.
Systematic Reviews, 4 (1)
[27] Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis
Lee, Ellen E.
Della Selva, Megan P.
Liu, Anson
Himelhoch, Seth
GENERAL HOSPITAL PSYCHIATRY, 2015, 37 (02) : 178 - 184
[28] Rasch analysis of the Chinese version of the clinically useful depression outcome scale in patients with major depressive disorder
Zhong, Jing
Ma, Hai-Yan
Wang, Xue-Mei
Huang, Xiao-Jie
Xu, Ming-Zhi
BMC PSYCHOLOGY, 2023, 11 (01)
[29] Improvement in Symptoms of Depression and Anxiety With Zuranolone Treatment in Patients With Major Depressive Disorder: HAM-A Analysis From the Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Waterfall Study
Kanes, Stephen J.
Clayton, Anita
Jung, JungAh
Brown, Colville
Lasser, Robert
Doherty, James
NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 187 - 188
[30] The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis
Jawad, Muhammad Youshay
Di Vincenzo, Joshua D.
Ceban, Felicia
Jaberi, Saja
Lui, Leanna M. W.
Gillissie, Emily S.
Alnafeesi, Yazen
Rosenblat, Joshua D.
McIntyre, Roger S.
EXPERT OPINION ON DRUG SAFETY, 2022, 21 (06) : 841 - 852

← 1 2 3 4 5 →